Our projects

TRQ001 - for acute migraine

An innovative, new treatment option with established therapeutic, clinical validation (active drug substance). EMA-reviewed and approved for Phase II clinical trials.

Attesting to our model, we achieved this stage of clincial development at a tiny fraction of the costs and much lower residual risks compared to conventional developments in this indication.

TRQ002 - bleeding shock

A new treatment modality with pre-clinical and clinical validation

TRQ003 - hypertension and end-organ protection

A super-charged Angiotensin IIr blocker therapy

TRQ004 - diet-induced dyslipidaemia

A novel, validated therapy approach to treat diet-induced dyslipidaemia and consequences